179 related articles for article (PubMed ID: 34342494)
1. Treatment patterns and outcomes among nontransplant newly diagnosed multiple myeloma patients in Spain.
Hernández-Rivas JÁ; Arnao M; Arguiñano Pérez JM; Rubio A; García EG; de Miguel D; Cherepanov D; Romanus D; Verleger K; Johnson C; Corman SL; Grande M; Persona EP
Future Oncol; 2021 Sep; 17(26):3465-3476. PubMed ID: 34342494
[TBL] [Abstract][Full Text] [Related]
2. Real-world treatment patterns and outcomes in non-transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom.
Mohty M; Knauf W; Romanus D; Corman S; Verleger K; Kwon Y; Cherepanov D; Cambron-Mellott MJ; Vikis HG; Gonzalez F; Gavini F; Ramasamy K
Eur J Haematol; 2020 Sep; 105(3):308-325. PubMed ID: 32418256
[TBL] [Abstract][Full Text] [Related]
3. Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma.
Landgren O; Sonneveld P; Jakubowiak A; Mohty M; Iskander KS; Mezzi K; Siegel DS
Leukemia; 2019 Sep; 33(9):2127-2143. PubMed ID: 31341235
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and treatment of multiple myeloma in Hunan Province.
Liu F; Cheng Q; Song K; Yu H; Li J; Zhang H; Hu G; Zhou M; Wang J; Ding Z; Luo Z; Peng T; Ding L; Zhao L; Liu J; He Y; Peng H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 47(4):497-504. PubMed ID: 35545345
[TBL] [Abstract][Full Text] [Related]
5. The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.
Paul B; Zhao Y; Loitsch G; Feinberg D; Mathews P; Barak I; Dupuis M; Li Z; Rein L; Wang E; Kang Y
Cancer Med; 2020 Aug; 9(16):5869-5880. PubMed ID: 32628819
[TBL] [Abstract][Full Text] [Related]
6. Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front-line regimens using the SEER-Medicare data.
Goto D; Khairnar R; Yared JA; Yong C; Romanus D; Onukwugha E; Slejko JF
Cancer Med; 2020 Jan; 9(2):626-639. PubMed ID: 31801177
[TBL] [Abstract][Full Text] [Related]
7. How should we treat newly diagnosed multiple myeloma patients?
Mateos MV; San Miguel JF
Hematology Am Soc Hematol Educ Program; 2013; 2013():488-95. PubMed ID: 24319223
[TBL] [Abstract][Full Text] [Related]
8. Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany.
Steinmetz HT; Singh M; Lebioda A; Gonzalez-McQuire S; Rieth A; Schoehl M; Poenisch W
Oncol Res Treat; 2020; 43(9):449-459. PubMed ID: 32694243
[TBL] [Abstract][Full Text] [Related]
9. Modified Hyper-CVAD With Proteasome Inhibition for Multiple Myeloma: A Single-Center Retrospective Analysis.
Narayan R; Galligan D; Lazar AA; Kim S; Fong R; Tan M; Lo M; Arora S; Shah N; Wong SW; Martin T; Wolf J
Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):e961-e985. PubMed ID: 32839138
[TBL] [Abstract][Full Text] [Related]
10. Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis.
Al Saleh AS; Visram A; Parmar H; Muchtar E; Buadi FK; Dispenzieri A; Warsame R; Lacy MQ; Dingli D; Leung N; Go RS; Gonsalves WI; Kourelis TV; Hayman SR; Kapoor P; Gertz MA; Kyle RA; Rajkumar SV; Kumar SK
Leuk Lymphoma; 2021 Dec; 62(12):3011-3018. PubMed ID: 34263694
[TBL] [Abstract][Full Text] [Related]
11. Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma.
Ntanasis-Stathopoulos I; Terpos E; Dimopoulos MA
Cancer J; 2019; 25(1):2-10. PubMed ID: 30694854
[TBL] [Abstract][Full Text] [Related]
12. Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis.
Teh BW; Harrison SJ; Worth LJ; Thursky KA; Slavin MA
Eur J Cancer; 2016 Nov; 67():21-37. PubMed ID: 27592069
[TBL] [Abstract][Full Text] [Related]
13. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma.
Dimopoulos MA; Jakubowiak AJ; McCarthy PL; Orlowski RZ; Attal M; Bladé J; Goldschmidt H; Weisel KC; Ramasamy K; Zweegman S; Spencer A; Huang JSY; Lu J; Sunami K; Iida S; Chng WJ; Holstein SA; Rocci A; Skacel T; Labotka R; Palumbo A; Anderson KC
Blood Cancer J; 2020 Feb; 10(2):17. PubMed ID: 32054831
[TBL] [Abstract][Full Text] [Related]
14. The real-world outcomes of multiple myeloma patients treated with daratumumab.
Szabo AG; Klausen TW; Levring MB; Preiss B; Helleberg C; Breinholt MF; Hermansen E; Gjerdrum LMR; Bønløkke ST; Nielsen K; Kjeldsen E; Iversen KF; Teodorescu EM; Dokhi M; Kurt E; Strandholdt C; Andersen MK; Vangsted AJ
PLoS One; 2021; 16(10):e0258487. PubMed ID: 34644367
[TBL] [Abstract][Full Text] [Related]
15. The emerging role of carfilzomib combination therapy in the management of multiple myeloma.
Moreau P
Expert Rev Hematol; 2014 Apr; 7(2):265-90. PubMed ID: 24521249
[TBL] [Abstract][Full Text] [Related]
16. [Proteasome inhibitors in first-line treatment of transplant-ineligible multiple myeloma patients].
Kuroda J; Shimura Y
Rinsho Ketsueki; 2017; 58(8):999-1005. PubMed ID: 28883286
[TBL] [Abstract][Full Text] [Related]
17. Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma.
López-Corral L; Caballero-Velázquez T; López-Godino O; Rosiñol L; Pérez-Vicente S; Fernandez-Avilés F; Krsnik I; Morillo D; Heras I; Morgades M; Rifon JJ; Sampol A; Iniesta F; Ocio EM; Martin J; Rovira M; Cabero M; Castilla-Llorente C; Ribera JM; Torres-Juan M; Moraleda JM; Martinez C; Vázquez A; Gutierrez G; Caballero D; San Miguel JF; Mateos MV; Pérez-Simón JA
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1703-1712. PubMed ID: 31054983
[TBL] [Abstract][Full Text] [Related]
18. Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation.
Wahab A; Rafae A; Faisal MS; Mushtaq K; Ehsan H; Khakwani M; Ashraf A; Rehan T; Ahmed Z; Shah Z; Khan A; Anwer F
Expert Rev Hematol; 2020 Dec; 13(12):1333-1347. PubMed ID: 33078986
[TBL] [Abstract][Full Text] [Related]
19. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.
Usmani SZ; Nahi H; Plesner T; Weiss BM; Bahlis NJ; Belch A; Voorhees PM; Laubach JP; van de Donk NWCJ; Ahmadi T; Uhlar CM; Wang J; Feng H; Qi M; Richardson PG; Lonial S
Lancet Haematol; 2020 Jun; 7(6):e447-e455. PubMed ID: 32470437
[TBL] [Abstract][Full Text] [Related]
20. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
Chari A; Parikh K; Ni Q; Abouzaid S
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
